MLTX MoonLake Immunotherapeutics
Price (delayed)
$38.05
Market cap
$2.44B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.89
Enterprise value
$2.26B
moonlake immunotherapeutics ag is a clinical-stage biopharmaceutical company leveraging revolutionary nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
Highlights
The debt is down by 23% year-on-year and by 16% since the previous quarter
The net income has dropped by 175% year-on-year and by 47% since the previous quarter
MoonLake Immunotherapeutics's EPS has shrunk by 159% YoY and by 49% QoQ
Key stats
What are the main financial stats of MLTX
Market
Valuations
Earnings
Shares outstanding
64.01M
Market cap
$2.44B
Enterprise value
$2.26B
Price to earnings (P/E)
N/A
Price to book (P/B)
5.44
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$143.09M
Net income
-$121.24M
EBIT
-$120.96M
EBITDA
-$119.58M
Free cash flow
-$117.11M
Per share
Balance sheet
Liquidity
EPS
-$1.89
EPS diluted
-$1.89
Free cash flow per share
-$1.86
Book value per share
$6.99
Revenue per share
$0
TBVPS
$7.6
Total assets
$477.93M
Total liabilities
$24.54M
Debt
$2.83M
Equity
$446.83M
Working capital
$451.82M
Debt to equity
0.01
Current ratio
21.11
Quick ratio
20.07
Net debt/EBITDA
1.49
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-23%
Return on equity
-24.3%
Return on invested capital
-69.4%
Return on capital employed
-26.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MLTX stock price
How has the MoonLake Immunotherapeutics stock price performed over time
Intraday
4.68%
1 week
-0.89%
1 month
-8.88%
1 year
-19.47%
YTD
-29.73%
QTD
-2.61%
Financial performance
How have MoonLake Immunotherapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$143.09M
Net income
-$121.24M
Gross margin
N/A
Net margin
N/A
The net income has dropped by 175% year-on-year and by 47% since the previous quarter
The operating income has dropped by 164% year-on-year and by 32% since the previous quarter
Growth
What is MoonLake Immunotherapeutics's growth rate over time
Valuation
What is MoonLake Immunotherapeutics stock price valuation
P/E
N/A
P/B
5.44
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
MoonLake Immunotherapeutics's EPS has shrunk by 159% YoY and by 49% QoQ
The price to book (P/B) is 19% lower than the last 4 quarters average of 6.4
MLTX's equity is down by 10% YoY and by 8% QoQ
Efficiency
How efficient is MoonLake Immunotherapeutics business performance
The company's return on assets has shrunk by 109% YoY and by 49% QoQ
The company's return on equity has shrunk by 101% YoY and by 50% QoQ
The ROIC has contracted by 2.8% from the previous quarter
Dividends
What is MLTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MLTX.
Financial health
How did MoonLake Immunotherapeutics financials performed over time
MLTX's total liabilities has surged by 88% year-on-year and by 8% since the previous quarter
MLTX's quick ratio has dropped by 61% year-on-year and by 19% since the previous quarter
The debt is 99% smaller than the equity
The debt is down by 23% year-on-year and by 16% since the previous quarter
MLTX's equity is down by 10% YoY and by 8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.